Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  SHANGHAI STOCK EXCHANGE  >  Shanghai Fosun Pharmaceutical Group    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL GROUP

(600196)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations
The feature you requested does not exist. However, we suggest the following feature:

Shanghai Fosun Pharmaceutical : POLL RESULTS OF THE RESOLUTION PROPOSED AT THE 2019 SECOND EXTRAORDINARY GENERAL MEETING HELD ON MONDAY, 21 OCTOBER 2019

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/21/2019 | 07:21am EDT

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥( 集 團 )股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

POLL RESULTS OF THE RESOLUTION PROPOSED AT

THE 2019 SECOND EXTRAORDINARY GENERAL MEETING

HELD ON MONDAY, 21 OCTOBER 2019

The board (the ''Board'') of directors (the ''Directors'') of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the ''Company'') is pleased to announce the poll results of the 2019 second extraordinary general meeting (the ''EGM'') held at Shanghai Film Art Center, No. 160 Xinhua Road, Shanghai, the People's Republic of China on Monday, 21 October at 1:30 p.m..

References are made to the notice of the EGM and the circular of the Company (the ''Circular''), both dated 3 September 2019. Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

As at the date of the EGM, (i) the total number of the issued shares of the Company (the ''Shares'') was 2,562,898,545 Shares, comprising 2,010,958,045 A Shares and 551,940,500 H Shares; and (ii) holders of 2,562,898,545 Shares (or authorized proxies) were entitled to attend and vote on the resolution proposed at the EGM. There were no Shares entitling the shareholders of the Company (the ''Shareholders'') to attend and vote only against the resolution at the EGM.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, no Shareholder was required to abstain from voting at the EGM.

- 1 -

ATTENDANCE AT THE EGM

Set out below are the details of the Shareholders and authorized proxies present at the EGM:

Number of Shareholders and authorized proxies

126

Including:

Number of A Shareholders

124

Number of H Shareholders

2

Total number of Shares carrying voting rights (shares)

1,339,607,103

Including:

Total number of Shares carrying voting rights held by

1,099,937,902

A Shareholders

Total number of Shares carrying voting rights held by

239,669,201

H Shareholders

Percentage of the total number of Shares (%)

52.2692

Including:

Number of A Shares as a percentage of the number of Shares of

42.9177

the Company

Number of H Shares as a percentage of the number of Shares of

9.3515

the Company

The EGM was convened in compliance with the requirements of the Company Law of the People's Republic of China and the Articles of Association, and was chaired by Mr. Chen Qiyu, the chairman of the Company.

In compliance with the requirements of the Hong Kong Listing Rules and Article 115 of the Articles of Association, BDO Limited, Grandall Law Firm (Shanghai), the Company's PRC legal advisers, Shareholder's representative and members of the supervisory committee of the Company acted as the scrutineers for the vote-counting at the EGM.

- 2 -

POLL RESULTS OF THE RESOLUTION PROPOSED AT THE EGM

The resolution at the EGM was voted by poll. The poll results in respect of the resolution proposed at the EGM are as follows:

Ordinary Resolution

Number of valid votes (%)

For

Against

Abstain

1.

To consider and approve the resolution in

1,321,163,595

3,558,462

14,885,046

relation to the entering into the Transaction

(98.6232%)

(0.2656%)

(1.1112%)

Agreement and the Rollover Agreement and

the transactions contemplated thereunder.

As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.

2.

To consider and approve the resolution in

260,369,841

104,223,472

8,532,200

relation to the proposed renewal of continuing

(69.7808%)

(27.9326%)

(2.2866%)

connected transactions as contemplated under

the Renewed Financial Services Agreement.

As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.

CERTIFICATION

As certified by and stated in the legal opinion issued by Grandall Law Firm (Shanghai), the Company's PRC legal adviser, the convening and holding of the EGM are in compliance with requirements of the laws, administrative regulations, the Rules of General Meetings of Listed Companies and the Articles of Association, the qualifications of the attendees of the EGM and the convener are legally valid, and the voting procedures and voting results of the EGM are legally valid.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Chen Qiyu

Chairman

Shanghai, PRC

21 October 2019

As at the date of this announcement, the executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang and Mr. Wu Yifang; the non-executive directors of the Company are Mr. Xu Xiaoliang, Mr. Wang Can, Ms. Mu Haining and Mr. Liang Jianfeng; and the independent non-executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

  • for identification purposes only

- 3 -

Disclaimer

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published this content on 21 October 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 October 2019 11:20:07 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SHANGHAI FOSUN PHARMACEUTI
10/21SHANGHAI FOSUN PHARMACEUTICAL : Poll results of the resolution proposed at the 2..
PU
10/15SHANGHAI FOSUN PHARMACEUTICAL : Announcement - on completion of the issuance of ..
PU
10/08SHANGHAI FOSUN PHARMACEUTICAL : Monthly return of equity issuer on movements in ..
PU
08/26SHANGHAI FOSUN PHARMACEUTICAL GROUP : Half-year results
CO
08/02SHANGHAI FOSUN PHARMACEUTICAL GROUP : Ex-dividend day for final dividend
FA
03/26SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma year net down 13% to RMB2.71 billio..
AQ
03/25SHANGHAI FOSUN PHARMACEUTICAL GROUP : Annual results
CO
03/20SHANGHAI FOSUN PHARMACEUTICAL (GROUP : annual earnings release
2018China's Junshi Biosciences raises $394 million after pricing IPO at bottom of..
RE
2018Shanghai Henlius up for Hong Kong IPO
AQ
More news
Financials (CNY)
Sales 2019 29 516 M
EBIT 2019 2 644 M
Net income 2019 3 296 M
Debt 2019 16 402 M
Yield 2019 1,58%
P/E ratio 2019 19,4x
P/E ratio 2020 17,2x
EV / Sales2019 2,64x
EV / Sales2020 2,26x
Capitalization 61 610 M
Chart SHANGHAI FOSUN PHARMACEUTICAL GROUP
Duration : Period :
Shanghai Fosun Pharmaceutical Group Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHANGHAI FOSUN PHARMACEUTI
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 32,97  CNY
Last Close Price 25,19  CNY
Spread / Highest target 46,9%
Spread / Average Target 30,9%
Spread / Lowest Target -8,90%
EPS Revisions
Managers
NameTitle
Yi Fang Wu President, CEO & Executive Director
Qi Yu Chen Co-Chairman
Fang Yao Co-Chairman
Qian Ren Chairman-Supervisory Board
Xiao Hui Guan CFO, Chief Accountant Officer & Senior VP
Sector and Competitors